# Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis

> **NCT00263601** · PHASE3 · COMPLETED · sponsor: **Allergopharma GmbH & Co. KG** · enrollment: 154 (actual)

## Conditions studied

- Grass Pollen Allergy

## Interventions

- **BIOLOGICAL:** Allergovit 6-grasses
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00263601
- **Lead sponsor:** Allergopharma GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2004-05
- **Final completion:** 2010-08
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2014-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00263601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00263601, "Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00263601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*